2018
441 Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Malignancies
Isufi I, Seropian S, Cooper D, Roberts K, Wilson L, Girardi M, Perreault S, Foss F. 441 Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Malignancies. Transplantation And Cellular Therapy 2018, 24: s307. DOI: 10.1016/j.bbmt.2017.12.353.Peer-Reviewed Original Research
2014
Poorer Prognosis of African-American Patients With Mycosis Fungoides: An Analysis of the SEER Dataset, 1988 to 2008
Nath SK, Yu JB, Wilson LD. Poorer Prognosis of African-American Patients With Mycosis Fungoides: An Analysis of the SEER Dataset, 1988 to 2008. Clinical Lymphoma Myeloma & Leukemia 2014, 14: 419-423. PMID: 24508350, PMCID: PMC4081527, DOI: 10.1016/j.clml.2013.12.018.Peer-Reviewed Original ResearchConceptsDisease-specific survivalAA raceRT utilizationRadiation therapyOverall survivalTumor stageMultivariate analysisInitial treatment modalityWorse overall survivalAfrican American patientsPublic-use databaseClinical factorsTumor RegistryAA patientsFemale patientsMycosis fungoidesWorse prognosisPoor prognosisFemale sexTreatment modalitiesAdvanced agePoor survivalPoorer PrognosisPatientsMedical care
2011
Stage Presentation and Clinical Outcome by Race for Patients with Mycosis Fungoides: A National Population Based Registry Study
Wilson L, Hinds G, Yu J. Stage Presentation and Clinical Outcome by Race for Patients with Mycosis Fungoides: A National Population Based Registry Study. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s634. DOI: 10.1016/j.ijrobp.2011.06.1882.Peer-Reviewed Original ResearchProphylactic Cranial Irradiation for High-Risk Patients with Locally Advanced Non-small Cell Lung Cancer
Park H, Decker R, Wilson L, Yu J. Prophylactic Cranial Irradiation for High-Risk Patients with Locally Advanced Non-small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s627. DOI: 10.1016/j.ijrobp.2011.06.1866.Peer-Reviewed Original Research
2005
The Impact of Radiotherapy for Post-operative Patients with Stage II or Stage III Non-Small Cell Lung Cancer Utilizing the Surveillance, Epidemiology, and End Results Database
Lally B, Wilson L. The Impact of Radiotherapy for Post-operative Patients with Stage II or Stage III Non-Small Cell Lung Cancer Utilizing the Surveillance, Epidemiology, and End Results Database. International Journal Of Radiation Oncology • Biology • Physics 2005, 63: s102-s103. DOI: 10.1016/j.ijrobp.2005.07.176.Peer-Reviewed Original Research
2002
Evaluation of Second Malignancy and Local Recurrence in Patients with T1 and T2 Squamo Cell Carcinoma (SCC) of the Larynx
Colasanto J, Wilson L, Haffty B. Evaluation of Second Malignancy and Local Recurrence in Patients with T1 and T2 Squamo Cell Carcinoma (SCC) of the Larynx. The Cancer Journal 2002, 8: 491. DOI: 10.1097/00130404-200211000-00035.Peer-Reviewed Original Research
2000
Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides
Wilson L, Jones G, Kim D, Rosenthal D, Christensen I, Edelson R, Heald P, Kacinski B. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. Journal Of The American Academy Of Dermatology 2000, 43: 54-60. PMID: 10863224, DOI: 10.1067/mjd.2000.105510.Peer-Reviewed Original ResearchConceptsTotal skin electron beam radiationCause-specific survivalProgression-free survivalErythrodermic mycosis fungoidesDisease-free survivalExtracorporeal photopheresisPrognosis of patientsMycosis fungoidesOverall survivalTotal skin electron beam therapyComplete response ratePercent of patientsManagement of patientsMonths of completionCancer Care OntarioTreatment 2 daysElectron beam therapyHematologic involvementComplete respondersStage IVAMedian ageCox regressionPatientsTherapeutic RadiologyYale University School
1998
Local Superficial Radiotherapy in the Management of Minimal Stage IA Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Wilson L, Kacinski B, Jones G. Local Superficial Radiotherapy in the Management of Minimal Stage IA Cutaneous T-Cell Lymphoma (Mycosis Fungoides). International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 109-115. PMID: 9422565, DOI: 10.1016/s0360-3016(97)00553-1.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaStage IA mycosis fungoidesT-cell lymphomaAdjuvant therapyLocal controlMycosis fungoidesSuperficial radiationSuperficial radiotherapyDistant skin sitesMedian fraction numberMedian surface doseComplete response rateExcellent local controlDry desquamationPrior therapyHematologic toxicityPrior radiationDistant failurePersistent diseaseMedian ageCutaneous malignanciesPathologic documentationSurface doseMild erythemaPatients
1996
Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 1996, 35: 69-73. PMID: 8682967, DOI: 10.1016/s0190-9622(96)90499-5.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaComplete responseT-cell lymphomaElectron beam therapySecond courseMedian disease-free intervalThird courseAdditional coursesBeam therapyDisease-free intervalTreatment of patientsAcceptable risk profileForm of therapyMedian doseMedian survivalMild erythemaPatientsInitial courseTherapyVariety of modalitiesRisk profileEntire groupLocalized radiationExtent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy
Quiros P, Kacinski B, Wilson L. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy. Cancer 1996, 77: 1912-1917. PMID: 8646693, DOI: 10.1002/(sici)1097-0142(19960501)77:9<1912::aid-cncr23>3.0.co;2-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBody Surface AreaChemotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRadiotherapy DosageRadiotherapy, High-EnergyRemission InductionRetrospective StudiesSkinSkin NeoplasmsSurvival RateConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaComplete clinical responseOverall survivalSkin involvementT-cell lymphomaMedian DFSPrognostic indicatorTotal skin electron beam radiation therapyToxicity of therapyElectron beam radiation therapyBeam radiation therapyTotal skin surfaceElectron beam therapyFree survivalClinical responsePrognostic significanceTumor nodulesRadiation therapyPatientsPatient recordsTherapyDiseaseBeam therapyMonths2158 Management of patients with T4 cutaneous T-cell lymphoma(CTCL) with total skin electron beam therapy(TSEBT) and adjuvant extracorporeal photochemotherapy(ECP)
Wilson L, Quiros P, Edelson R, Heald P, Kacinski B. 2158 Management of patients with T4 cutaneous T-cell lymphoma(CTCL) with total skin electron beam therapy(TSEBT) and adjuvant extracorporeal photochemotherapy(ECP). International Journal Of Radiation Oncology • Biology • Physics 1996, 36: 355. DOI: 10.1016/s0360-3016(97)85734-3.Peer-Reviewed Original Research2159 Total skin electron beam therapy(TSEBT) followed by adjuvant psoralen/ultraviolet A light (PUVA) in the management of patients with T1 and T2 cutaneous T-cell lymphoma (CTCL)
Quiros P, Kacinski B, Heald P, Edelson R, Braverman I, Wilson L. 2159 Total skin electron beam therapy(TSEBT) followed by adjuvant psoralen/ultraviolet A light (PUVA) in the management of patients with T1 and T2 cutaneous T-cell lymphoma (CTCL). International Journal Of Radiation Oncology • Biology • Physics 1996, 36: 355. DOI: 10.1016/s0360-3016(97)85733-1.Peer-Reviewed Original Research
1995
Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation
Licata A, Wilson L, Braverman I, Feldman A, Kacinski B. Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation. JAMA Dermatology 1995, 131: 432-435. DOI: 10.1001/archderm.1995.01690160060009.Peer-Reviewed Original ResearchTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinoma
1994
Novel prognostic factors predictive of prolonged relapse-free and overall survival in advanced stage CTCL (mycosis fungoides) patients treated with total skin electron beam therapy
Kacinski B, Wilson L, Quiros P, Kolenik S, Heald P, Edelson R, Braverman I. Novel prognostic factors predictive of prolonged relapse-free and overall survival in advanced stage CTCL (mycosis fungoides) patients treated with total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 268. DOI: 10.1016/0360-3016(94)90823-0.Peer-Reviewed Original ResearchAdditional courses of total skin electron beam therapy [TSEBT] in the retreatment of patients with cutaneous t-cell lymphoma [CTCL]
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy [TSEBT] in the retreatment of patients with cutaneous t-cell lymphoma [CTCL]. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 269. DOI: 10.1016/0360-3016(94)90825-7.Peer-Reviewed Original Research
1993
Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers
Wilson L, Beinfield M, McKhann C, Haffty B. Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers. Cancer 1993, 72: 137-142. PMID: 8389664, DOI: 10.1002/1097-0142(19930701)72:1<137::aid-cncr2820720126>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsIpsilateral breast cancerConservative surgeryRadiation therapyRecurrence rateBreast cancerBreast recurrence rateChest wall progressionIpsilateral breast recurrenceActuarial survival rateEvidence of diseaseLocal recurrence rateManagement of patientsSubsequent local recurrenceInvasive lobular histologyBreast recurrenceLobular histologyMedian doseMetastatic diseaseLocal recurrenceThird patientRegional lymphaticsSeparate lesionsSingle lesionSame breastPatientsAdjuvant Extracorporeal Photoimmunotherapy or adjuvant adriamyciwcytoxan chemotherapy both prolong survival for cutaneous T-cell lymphoma (CTCL, MYCOSIS FUNGOIDES) patients treated with total skin electron beam therapy (TSEBT).
Kacinaki B, Wilson L, Goodrich A, Edelson R, Heald P, Braverman I. Adjuvant Extracorporeal Photoimmunotherapy or adjuvant adriamyciwcytoxan chemotherapy both prolong survival for cutaneous T-cell lymphoma (CTCL, MYCOSIS FUNGOIDES) patients treated with total skin electron beam therapy (TSEBT). International Journal Of Radiation Oncology • Biology • Physics 1993, 27: 186-187. DOI: 10.1016/0360-3016(93)90727-d.Peer-Reviewed Original Research